Videos

Forward Thinking to Improve SUDEP Prevention, Awareness: Orrin Devinsky, MD

Key opinion leaders explain the burden of disease that accompanies preventative migraine treatment.

Orrin Devinsky, MD

November 25th 2021

Choosing Treatments for Patients With Multiple Sclerosis: Devon Conway, MD

The director of the Comprehensive Epilepsy Center at NYU Langone provided closing thoughts on how clinicians can begin to shift gears from research to prevention of SUDEP. [WATCH TIME: 2 minutes]

Devon Conway, MD

November 24th 2021

Treating Insomnia With Related Comorbid Conditions: Michael Thorpy, MD

Discussing newer treatment options in the MS field, the staff neurologist in the Neurological Institute’s Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic noted that patient preference can play a part in the decision-making process. [WATCH TIME: 3 minutes]

Michael J. Thorpy, MD

November 24th 2021

New Medications for Multiple Sclerosis Treatment: Devon Conway, MD

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center provided knowledge on how the presence of other comorbid sleep disorders affects patients with insomnia. [WATCH TIME: 2 minutes]

Devon Conway, MD

Ubrogepant for Acute Migraine Treatment

The staff neurologist in the Neurological Institute’s Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic discussed emerging treatments in the MS field. [WATCH TIME: 2 minutes]

David Kudrow, MD

The Impact of CGRP Antagonists on Chronic Migraine

A migraine specialist examines the efficacy and safety of oral CGRP antagonist ubrogepant for the acute treatment of migraine.

David Kudrow, MD

Role Heart Rate Variability Plays in SUDEP Research, Prevention: Orrin Devinsky, MD

Dr David Kudrow discusses how CGRP antagonist treatments have affected chronic migraine, including the effect on quality of life.

Orrin Devinsky, MD

Early Initiation of Therapy for RRMS

The director of the Comprehensive Epilepsy Center at NYU Langone discussed the necessary steps in validating and utilizing heart rate variability as a biomarker for SUDEP. [WATCH TIME: 3 minutes]

Parkinson’s Disease: Advice for Community Neurologists

The rationale for early treatment initiation for patients with relapsing-remitting multiple sclerosis.

Stuart H. Isaacson, MD, FAAN;Laxman Bahroo, DO;Khashayar Dashtipour, MD;Daniel E. Kremens, MD, JD;William Ondo, MD

Appropriate Diagnosis and Management of RRMS

Expert neurologists provide insight on how to decide on an on-demand therapy for Parkinson’s disease and provide some general advice.

Sublingual Apomorphine for Parkinson’s Disease

The patient symptoms that help neurologists distinguish relapsing and remitting multiple sclerosis from other forms of the disease, and recommendations regarding the best timing to initiate therapy.

Stuart H. Isaacson, MD, FAAN;Laxman Bahroo, DO;Khashayar Dashtipour, MD;Daniel E. Kremens, MD, JD;William Ondo, MD

Realistic Outlook for Mesenchymal Stem Cells, Other Treatments in Progressive MS: Jeffrey Cohen, MD

Key opinion leaders explain the use of sublingual apomorphine and trimethobenzamide for Parkinson’s disease.

Jeffrey Cohen, MD

November 22nd 2021

Next Steps, Future Development of FUS Technology in Alzheimer Disease: Ali Rezai, MD

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed when clinicians should anticipate new therapies to treat progressive MS. [WATCH TIME: 2 minutes]

Ali Rezai, MD

November 22nd 2021

AUPN Leadership Minute Episode 16: Turning Your Clinic Into a Source of Scholarly Activity

The executive chair of the Rockefeller Neuroscience Institute at West Virginia University discussed the potential of focused ultrasound for patients with AD, as well as key takeaways for clinicians from a recent study. [WATCH TIME: 5 minutes]

Selim R. Benbadis, MD, FAAN, FACNS, FAES;Rohit Das, MD

November 20th 2021

AMX0035 Shows Safety in Alzheimer Disease, Outcomes of Urgent Prevention in TIA, FDA Grants IDE to NeuroPace's RNS System

Episode 16 of the AUPN Leadership Minute features Rohit Das, MD, of UT Southwestern Medical Center; and Selim R. Benbadis, MD, FAAN, FACNS, FAES, University of South Florida Morsani College of Medicine. [WATCH TIME: 4 minutes]

November 20th 2021

Applications of MRI-Guided FUS in Alzheimer Disease: Ali Rezai, MD

Neurology News Network for the week ending November 20, 2021.

Ali Rezai, MD

Cannabidiol’s Approval on Dravet and Lennox-Gastaut Syndromes

The executive chair of the Rockefeller Neuroscience Institute at West Virginia University spoke on how technology can be used to open the blood-brain barrier in patients with AD. [WATCH TIME: 7 minutes]

Treatment Options and Patient Selection for Dravet and Lennox-Gastaut Syndromes

Elizabeth Thiele, MD, PhD, and Elaine C. Wirrell, MD, discuss the FDA approval of cannabidiol as an oral solution for the treatment of seizures, specifically for both Dravet and Lennox-Gastaut syndromes.

Goals of Preventative Therapy for Migraine

Two experts detail the current treatment options for Dravet and Lennox-Gastaut syndromes and how they select which patients should use a specific drug.

Jessica Ailani, MD;Andrew C. Charles, MD;Stephanie J. Nahas, MD;Christopher Gottschalk, MD;Rebecca Erwin Wells, MD, MPH

Migraine: A Historic Perspective on Preventative Therapy

Expert neurologists share their goals and patient considerations for preventive migraine therapy.

Jessica Ailani, MD;Stephanie J. Nahas, MD;Christopher Gottschalk, MD;Andrew C. Charles, MD;Rebecca Erwin Wells, MD, MPH

Pitolisant for Narcolepsy and EDS: FDA Approval and Personal Experience

Andrew C. Charles, MD, provides a historical perspective on the agents traditionally used for preventive migraine therapy.

Chris Winter, MD

Parkinson Disease: SQ Apomorphine Hydrochloride for Morning OFF Episodes

Expert neurologist and sleep specialist Chris Winter, MD, discusses the FDA approval of pitolisant for patients with narcolepsy and excessive daytime sleepiness in the context of his own experience with this novel agent.

Peter A. LeWitt, MD

Narcolepsy: Evaluating and Addressing Excessive Daytime Sleepiness

Expert insight on the mechanism of action and use of subcutaneous apomorphine hydrochloride in patients with Parkinson disease.

Chris Winter, MD

Parkinson Disease: Levodopa Inhalation Powder for Morning OFF Episodes

Insight on the proper evaluation of excessive daytime sleepiness in patients with narcolepsy, as well as agents that have been used to manage this condition.

Peter A. LeWitt, MD

Heart Rate Variability’s Role in Potential SUDEP-Predicting Modalities: Orrin Devinsky, MD

Peter A. LeWitt, MD, considers the mechanism of action and use of levodopa inhalation powder in patients with Parkinson disease.

Orrin Devinsky, MD

UC San Diego Health: Institutional Perspectives in Neurology, Chaired by Jennifer Graves, MD, PhD, MAS

The director of the Comprehensive Epilepsy Center at NYU Langone provided insight on whether a newly discovered biomarker can play a role in the creation of modalities to detect SUDEP risk. [WATCH TIME: 3 minutes]

Incorporation of Registered Dietitians in MS Care: Tyler Titcomb, PhD, RDN, IFMCP

Chaired by Jennifer Graves, MD, PhD, MAS, the presentations also feature UC San Diego Health experts Jenelle Raynowska, MD; Jennifer Yang, MD; and Anastasie Dunn-Pirio, MD. [WATCH TIME: 1 hour, 23 minutes]

Tyler Titcomb, PhD, RDN, IFMCP

November 18th 2021

Therapeutic Approaches to Fatigue in Multiple Sclerosis: Anna Kratz, PhD

The postdoctoral scholar at the University of Iowa commented on why the multiple sclerosis field should lean on registered dietitians to help alleviate symptoms of patients with multiple sclerosis. [WATCH TIME: 2 minutes]

Anna Kratz, PhD

November 17th 2021